Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | CTSG | P08311 | 3/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.40 |
| ▸ | CMA1 | P23946 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19027138 | 0.85 | PRSS1 (0.37) | PRSS1CTSGCTRB1CMA1CNR2 | |
| SCHEMBL19352340 | 0.85 | PRSS1 (0.37) | PRSS1CTSGCTRB1CMA1CNR2 | |
| SCHEMBL19536294 | 0.85 | PRSS1 (0.37) | PRSS1CTSGCTRB1CMA1CNR2 | |
| SCHEMBL15948716 | 0.85 | PRSS1 (0.37) | PRSS1CTSGCTRB1CMA1CNR2 | |
| SCHEMBL15948720 | 0.81 | CYP1A2 (0.43) | — | |
| SCHEMBL3832552 | 0.81 | MEN1 (0.33) | — | |
| SCHEMBL20514686 | 0.79 | MMP1 (0.34) | PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL20514687 | 0.79 | MMP1 (0.34) | PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL13568005 | 0.78 | AAK1 (0.34) | — | |
| SCHEMBL15948786 | 0.78 | CTSK (0.37) | PRSS1CTSGCTRB1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017155923-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017106710-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | PRSS1 3813/4885CTSG 1970/4885CTRB1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.